GenomeDx
NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
GenomeDx Biosciences to Pay $2M to Settle Allegations of Improper Medicare Billing
The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier
Noridian GBA has issued the LCD for use of the Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer.